Who are Nitrous oxide gas for inhalation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Sevoflurane+Nitrous oxide, Sevoflurane, Isoflurane, Desflurane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nitrous-oxide-gas-for-inhalation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nitrous oxide gas for inhalation — Competitive Intelligence Brief

Nitrous oxide gas for inhalation (Nitrous oxide gas for inhalation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dissociative anesthetic. Area: Anesthesia and Acute Pain Management.

marketed Dissociative anesthetic NMDA receptor Anesthesia and Acute Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Nitrous oxide gas for inhalation (Nitrous oxide gas for inhalation) — Unity Health Toronto. Nitrous oxide acts as a dissociative anesthetic and analgesic by modulating NMDA receptor activity and enhancing inhibitory neurotransmission in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nitrous oxide gas for inhalation TARGET	Nitrous oxide gas for inhalation	Unity Health Toronto	marketed	Dissociative anesthetic	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Sevoflurane+Nitrous oxide	Sevoflurane+Nitrous oxide	Huazhong University of Science and Technology	marketed	General anesthetic (volatile anesthetic + inhalational anesthetic)	GABA receptors, NMDA receptors
Sevoflurane, Isoflurane, Desflurane	Sevoflurane, Isoflurane, Desflurane	University Hospital, Basel, Switzerland	marketed	Volatile anesthetic	GABA-A receptor, NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dissociative anesthetic class)

Rebecca Price · 1 drug in this class
The University of Hong Kong · 1 drug in this class
Unity Health Toronto · 1 drug in this class
University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nitrous oxide gas for inhalation — Competitive Intelligence Brief. https://druglandscape.com/ci/nitrous-oxide-gas-for-inhalation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab